(DAT, n = 18); liposomal doxorubicin (DT, n = 1); paclitaxel and bevacizumab (TAT, n = 2); paclitaxel (TT, n = 1); carboplatin and bevacizumab (CAT, n = 1). Response rate [complete response (CR) + partial response (PR)] was 25% across all regimens; 32% in the anthracycline-based regimens [DAT and DT (CR = 2, PR = 4; N = 19) ]. An additional two patients achieved stable disease (SD) ≥6 months [total SD ≥6 months/CR/PR = 8 (33%)]. Molecular aberrations in the PI3K pathway were common: PIK3CA mutation = 6/15 (40%), PTEN mutation = 3/11 (27%), and PTEN loss = 2/11 (18%). A point mutation in the NF2 gene (K159fs*16; NF2 alterations can activate mTor) was found in one patient who attained CR (3+ years). Of the eight patients who achieved SD ≥6 months/CR/PR, all 4 patients with available tissue had a molecular aberration that activate the PIK3CA/Akt/mTOR axis: PIK3CA mutation = 2; PTEN loss = 1; NF2 aberration = 1.
Conclusions: DAT has activity in MpBCs including complete CRs. Molecular aberrations that can activate the PI3 K/Akt/mTOR axis are common in MpBC. Key words: metaplastic breast cancer, liposomal doxorubicin, bevacizumab, temsirolimus introduction MpBCs are defined as invasive carcinomas that have either squamous or mesenchymal differentiation and are commonly TNBC [1] . Despite variation in prognosis depending on grade and histologic variant, high-grade MpBCs are relatively chemorefractory and carry a worse prognosis than nonmetaplastic, triple-negative breast cancers (TNBCs) [2] [3] [4] [5] [6] [7] .
Advances in molecular testing have further characterized TNBCs suggesting that subsets such as 'claudin-low', 'mesenchymal', or 'mesenchymal-stem cell like' are enriched in epithelial-to-mesenchymal transition (EMT), maintain stem cell-like characteristics, have PI3K pathway activation, and respond to PI3K inhibitors in preclinical models [8, 9] . Further characterization of claudin-low tumors revealed that 20%-30% are MpBCs [10] . Like claudin-low and mesenchymal/mesenchymal-stem cell-like tumors, MpBCs are also enriched in EMT, display PI3K pathway activation, and commonly carry PIK3CA mutations [11] . MpBCs also show strong correlation with a circulating stem cell-derived genomic profile heavily weighted for PI3K activity [11, 12] . Thus, treatment regimens that induce response in MpBCs may be used to treat the subsets of TNBC that lack metaplastic morphology, but share similar molecular characteristics. Given these molecular features, we report outcomes of patients with MpBC who were treated within the M.D. Anderson Cancer Center (MDACC) using regimens containing the mTOR inhibitor temsirolimus. Data from the first five patients treated have been previously published but were included to capture the entire experience for this rare cancer subtype [13] .
patients and methods

patient selection and data collection
Patients who carried a diagnosis of MpBC (invasive myoepithelial carcinoma for one patient) confirmed by pathology review at MDACC were treated in accordance with MDACC internal review board (IRB) guidelines. Response assessments occurred every 6-12 weeks using Response Evaluation Criteria in Solid Tumors (RECIST) [14] .
molecular correlative studies
When archived tissue was available, DNA was analyzed by polymerase chain reaction (PCR)-based DNA sequencing method for select genes of interest, particularly PIK3CA mutations [15, 16] . After January 2011, the assay was changed to mass spectrometric detection (Sequenom MassARRAY) [17] . In some patients, loss of PTEN was measured using immunohistochemistry (DAKO, Carpinteria, CA). Genes analyzed by PCR-based sequencing were not re-analyzed by Sequenom. Two patients' tumors underwent next-generation sequencing through Foundation Medicine (182 and 236 gene panel, Cambridge, MA).
results
patients and treatment
From May 2009 until September 2012, 23 patients were treated using six different temsirolimus-based therapy regimens (1 patient treated on two separate trials), yielding 24 analyzable outcomes ( Table 1 ). All but one patient had metastatic cancer and this patient had T4, locally advanced cancer that was unresponsive to neoadjuvant anthracycline-based chemotherapy. All patient tumors were negative for ER/PR or HER2 with the majority (91%) having visceral disease. The most common histology was sarcomatoid carcinomas [including keratin-positive, pure sarcomatoid morphology (n = 7) or both sarcomatoid and epithelial components (n = 7)], followed by matrix-producing carcinomas (n = 7) Table 1 . All of the matrix-producing carcinomas had chondroid or chondromyxoid stroma. Median number of prior chemotherapy regimens was 2 (range 0-7).
All patients received therapy with the temsirolimus, most in combination with chemotherapy ± bevacizumab ( Table 2) . Liposomal doxorubicin was the usual chemotherapy backbone (n = 19), followed by paclitaxel (n = 3; including one patient previously treated with DAT) and carboplatin (n = 1). One patient received temsirolimus alone. Several patients (n = 6) who began therapy with liposomal doxorubicin lost access during a nationwide drug shortage and received targeted agents alone for ∼6 months. Two patients developed PD and discontinued therapy; one subsequently received therapy with PAT.
efficacy
The response rate [complete response (CR)/partial response (PR)] to PI3K/Akt/mTor pathway-directed therapy in treated patients (n = 24 outcomes) with MpBC was 25% (n = 6). All responding patients received liposomal doxorubicin for a RR of 32% to the DAT/DT regimens. One patient attained a CR by RECIST with DAT after eight cycles of therapy (two without bevacizumab due to toxicity) followed by temsirolimus alone for a year before transitioning to oral everolimus (10 mg daily), which she continues to date (4 years on) without evidence of Figure 1 ). Notably, this patient was treated with DAT as first-line therapy for her metastatic disease and was anthracycline naïve as she had only received prior docetaxel and cyclophosphamide (five cycles) in the adjuvant setting. A second patient who achieved CR was also treated with DAT [ progression free survival (PFS) = 22 months] (Table 4) . This patient had received four cycles of doxorubicin and cyclophosphamide in the adjuvant setting and was treated with carboplatin and paclitaxel followed by radiation for a chest wall recurrence prior to beginning DAT for metastatic disease in the lung. Four patients achieved PRs; three were treated with DAT; and one with DT. Two additional patients receiving PI3K pathway-directed therapy in combination with chemotherapy achieved SD ≥6 months (DAT = 1, PAT = 1) for an overall clinical benefit rate (CBR = SD ≥6 months/CR/PR) of 35% (n = 8 of 23 patient outcomes) and 37% in those receiving DAT/DT.
toxicity
Toxicities associated with DAT have been previously published and thus not detailed here [18] . However, it is important to note that one patient with a history of postobstructive pneumonia died of pneumonia during cycle 2 of therapy with DAT. A second patient treated with DAT had grade 3 congestive heart failure simultaneously with disease progression within the brain and chose to enter hospice, so it is unknown if her heart function improved after discontinuing therapy.
molecular correlative studies
Archived tissue was available for molecular analysis in 16 of 23 patients (one patient had breast recurrence and lung metastasis analyzed) (Tables 3-5) . Half of the samples tested (n = 8) were from primary tumors and half (n = 8) were from recurrent disease (4 from local recurrences and 4 from distant metastatic disease). Nine samples were evaluated prior to 2011 using PCRbased sequencing and 7 were evaluated using mass spectrometric detection (Table 5 ). No genes analyzed by PCR-based sequencing were reanalyzed by mass spectrometric techniques; however, tumor samples from patient 15 underwent analysis of different genes, initially by PCR (PIK3CA, PTEN) and then by mass spectrometric techniques (BRAF, KRAS, AKT1). A molecular aberration in the PI3K pathway was detected in 69% of patients tested ( Table 5 ). The majority harbored mutations in PIK3CA (6 of 15, 40%) or PTEN aberrations (5 of 15, 33%). Two of 11 (18%) had loss of PTEN by IHC and 3 of 11 (27%) harbored aberrations in PTEN (Table 5 ). Both patients who achieved CRs harbored molecular aberrations: one a PIK3CA mutation, the other an NF2 mutation (Table 5) .
Of the four patients who attained PR, one had PTEN loss and the other three did not have adequate tissue available for complete testing (Table 3) ; of the two patients who achieved CR, both had aberrations that could lead to PI3K pathway activation (Tables 4 and 5 ). Overall, of the eight patients with clinical benefit, all four with correlative tissue had an aberration that could lead to activation of the PI3K/Akt/mTOR axis (Table 3 ). An additional patient with a detectable mutation in PIK3CA (H1047R) died of pneumonia during cycle 2 of therapy with DAT and was, thus, not assessed for response using RECIST; however, a reduction in size of her lung metastases was noted on cycles of therapy; considered a CR. She transitioned to oral everolimus (10 mg daily) and later received consolidative stereotactic radiation to her isolated, treated pulmonary metastasis. PFS was 22 months (developed chest wall recurrence).
chest X-ray prior to starting her second cycle of DAT. Not all patients with mutations responded. A patient with detected PIK3CA mutation E545K developed rapid disease progression after two cycles of DAT and the patient with detected PIK3CA mutations E545A and H1047Y developed disease progression after four cycles of DAT.
discussion
We describe the largest prospective series documenting treatment of MpBC, a rare but historically aggressive subtype of TNBC. MpBC includes a spectrum of histologic types, usually high grade and considered chemo-refractory. In retrospective series short-lived, partial responses have been noted with doxorubicin in patients with metastatic disease [5, 19] . Our prospectively collected data demonstrates that a variety of aberrations in the PI3K/Akt/mTor axis are a hallmark of these patients. Indeed, 10 of 16 patients with available tissue had an aberration in one or more of the following genes that affect this pathway (Table 5) : PIK3CA, PTEN, NF2, or PIK3R1. Since next-generation sequencing was not available for many patients, it is plausible that other patients who had less comprehensive molecular testing might have also harbored an aberration in this pathway. Additionally, we identified a CR/PR rate of 26% using chemotherapy with temsirolimus (±bevacizumab) and a 32% CR/PR rate with DAT/DT. Responses to DAT/DT included 2 CRs, one ongoing (with maintenance everolimus) 3+ years after discontinuing protocol therapy; time to progression from initiation of therapy in the second patient was 22 months.
Additionally, two other patients attained SD for ≥6 months for a CBR of 33% overall, 35% among those who received chemotherapy with temsirolimus (±bevacizumab) and 37% in those treated with DAT/DT. These response rates are consistent with rates published for PI3K-directed therapy in nonbreast cancer patients whose tumors harbor PIK3CA mutations [15, 16, 20, 21] . Most patients also received bevacizumab as a component of their therapeutic regimen. MpBCs commonly express VEGF and HIF-1, suggesting bevacizumab may be key to the success of the DAT regimen [22, 23] .
The regimens were generally well tolerated with expected myelosuppression, mucositis, hand-foot syndrome, dyslipidemia and rarely pneumonitis [18] . One death occurred from postobstructive pneumonia and one patient had grade 3 congestive heart failure during DAT.
Though considered rare, MpBCs share similar molecular features to claudin-low and mesenchymal/mesenchymal-stem celllike tumors, subsets comprising up to 30% of TNBCs [8, 9, 11] . In fact, MpBCs make-up a portion of tumors molecularly characterized as claudin-low [10] . Unlike other mesenchymal tumors, MpBCs can be identified using microscopy, thus have undergone more extensive molecular characterization. We have confirmed previously published rates of PIK3CA/PTEN mutations rates in MpBC and one CR tumor harbored a PIK3CA mutation. Additionally, a patient with durable CR (3+ years) to therapy exhibited NF2 mutation. NF2 encodes merlin, a negative regulator of the mammalian target of rapamycin complex 1 (mTORC1). Loss of function mutations in NF2 is associated with sensitivity to rapamycin in preclinical models of mesothelioma [24] . Interestingly, a durable complete response was seen with single-agent everolimus in bladder cancer with an NF2 nonsense mutation; further corroborating the potential for mTOR dependence in tumors with aberrations in NF2 [25] . Additionally, bevacizumab ± mTOR inhibition has reduced schwannomas, stabilized disease, and/or improved in symptoms in neurofibromatosis type 2 [26] [27] [28] . Trials are ongoing to determine the role of rapamycin analogs in neurofibromatosis [29, 30] .
While the association of molecular aberrations with treatment response requires confirmation, three of six patients with CR or PR potentially activated the PI3K/Akt/mTOR axis (PIK3CA mutation, n = 1; PTEN loss, n = 1; NF2 aberration, n = 1; tissue unavailable in the other three). Both the patient with CR and another patient with SD ≥6 months had PIK3CA/H1047R mutation that is associated with response to mTOR inhibitors in early phase trials.
This study has important limitations. Notably, a range of regimens were employed, but each included temsirolimus, and all CRs and PRs occurred in regimens where liposomal doxorubicin (±bevacizumab) were included. Correlative data were also limited by tissue availability, although several molecular aberrations linked to activation of the PI3K/Akt/mTOR were identified. All patients with clinical benefit (CR/PR/SD ≥6months) and available tissue for molecular testing demonstrated these anomalies. Finally, comparative data consist of small, retrospective analyses involving diverse treatments.
In conclusion, patients with advanced MpBC harbor diverse molecular abnormalities potentially actionable by temsirolimusbased therapies which may achieve durable CR. These promising results justify exploration of the DAT regimen in a randomized clinical trial, including molecular correlates and nationwide recruitment of patients with this rare tumor subtype. disclosure RK receives consultant funds from Sequenom and is a founder of RScueRx, Inc. All remaining authors have declared no conflicts of interest.
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